Cybin (CYBN) Competitors $7.21 -0.17 (-2.30%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$7.23 +0.02 (+0.28%) As of 03/25/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CYBN vs. DNTH, LENZ, CRMD, SION, ORGO, ABUS, SANA, CDXC, KALV, and MGTXShould you be buying Cybin stock or one of its competitors? The main competitors of Cybin include Dianthus Therapeutics (DNTH), LENZ Therapeutics (LENZ), CorMedix (CRMD), Sionna Therapeutics (SION), Organogenesis (ORGO), Arbutus Biopharma (ABUS), Sana Biotechnology (SANA), ChromaDex (CDXC), KalVista Pharmaceuticals (KALV), and MeiraGTx (MGTX). These companies are all part of the "pharmaceutical products" industry. Cybin vs. Dianthus Therapeutics LENZ Therapeutics CorMedix Sionna Therapeutics Organogenesis Arbutus Biopharma Sana Biotechnology ChromaDex KalVista Pharmaceuticals MeiraGTx Cybin (NYSE:CYBN) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment. Do analysts prefer CYBN or DNTH? Cybin presently has a consensus price target of $86.00, indicating a potential upside of 1,092.79%. Dianthus Therapeutics has a consensus price target of $54.33, indicating a potential upside of 197.07%. Given Cybin's higher probable upside, equities analysts plainly believe Cybin is more favorable than Dianthus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Which has preferable valuation & earnings, CYBN or DNTH? Dianthus Therapeutics has higher revenue and earnings than Cybin. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.38-1.65Dianthus Therapeutics$6.24M94.24-$43.56M-$2.60-7.03 Is CYBN or DNTH more profitable? Cybin has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. Dianthus Therapeutics' return on equity of -21.68% beat Cybin's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Dianthus Therapeutics -1,250.32%-21.68%-20.88% Does the MarketBeat Community favor CYBN or DNTH? Dianthus Therapeutics received 10 more outperform votes than Cybin when rated by MarketBeat users. However, 100.00% of users gave Cybin an outperform vote while only 96.30% of users gave Dianthus Therapeutics an outperform vote. CompanyUnderperformOutperformCybinOutperform Votes16100.00% Underperform VotesNo VotesDianthus TherapeuticsOutperform Votes2696.30% Underperform Votes13.70% Which has more volatility & risk, CYBN or DNTH? Cybin has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Do insiders and institutionals hold more shares of CYBN or DNTH? 17.9% of Cybin shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor CYBN or DNTH? In the previous week, Cybin had 1 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 2 mentions for Cybin and 1 mentions for Dianthus Therapeutics. Cybin's average media sentiment score of 1.58 beat Dianthus Therapeutics' score of 0.73 indicating that Cybin is being referred to more favorably in the media. Company Overall Sentiment Cybin Very Positive Dianthus Therapeutics Positive SummaryDianthus Therapeutics beats Cybin on 12 of the 18 factors compared between the two stocks. Remove Ads Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYBN vs. The Competition Export to ExcelMetricCybinPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$154.85M$6.99B$5.68B$19.75BDividend YieldN/A2.72%4.55%3.75%P/E Ratio-1.657.2324.5534.05Price / SalesN/A230.77395.7228.57Price / CashN/A65.6738.1617.54Price / Book0.676.617.064.63Net Income-$57.88M$142.13M$3.19B$1.02B7 Day Performance-4.12%1.72%0.18%0.14%1 Month Performance-12.71%2.31%5.53%-1.17%1 Year PerformanceN/A-5.07%14.21%7.30% Cybin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYBNCybin2.7817 of 5 stars$7.21-2.3%$86.00+1,092.8%N/A$154.85MN/A-1.6550DNTHDianthus Therapeutics1.3268 of 5 stars$21.97+3.0%$52.14+137.3%-41.0%$650.25M$6.24M-8.7980High Trading VolumeLENZLENZ Therapeutics2.1712 of 5 stars$23.59-7.3%$35.40+50.1%+61.9%$648.75MN/A0.00110Earnings ReportAnalyst RevisionCRMDCorMedix2.0388 of 5 stars$10.47flat$16.00+52.8%+79.9%$635.29M$12.26M-12.9330Earnings ReportAnalyst ForecastOptions VolumeNews CoverageGap DownSIONSionna TherapeuticsN/A$14.89-0.6%$38.50+158.6%N/A$633.14MN/A0.0035Earnings ReportORGOOrganogenesis3.1113 of 5 stars$4.97-0.8%$5.50+10.7%+99.2%$630.34M$482.04M-82.83950ABUSArbutus Biopharma2.2125 of 5 stars$3.28-0.6%$5.50+67.7%+35.3%$621.53M$6.74M-7.6390Upcoming EarningsSANASana Biotechnology3.1032 of 5 stars$2.77-5.5%$12.25+342.2%-76.3%$618.46MN/A-1.98380News CoverageCDXCChromaDex4.3939 of 5 stars$7.94+1.3%$9.03+13.8%N/A$617.34M$99.60M794.79120KALVKalVista Pharmaceuticals4.4803 of 5 stars$12.49-0.9%$23.80+90.6%+12.3%$617.23MN/A-3.43100MGTXMeiraGTx4.7042 of 5 stars$7.87+1.0%$24.50+211.3%+21.5%$615.06M$13.93M-6.50300High Trading Volume Remove Ads Related Companies and Tools Related Companies DNTH Competitors LENZ Competitors CRMD Competitors SION Competitors ORGO Competitors ABUS Competitors SANA Competitors CDXC Competitors KALV Competitors MGTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CYBN) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
